FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4306160147> ?p ?o ?g. }

• W4306160147 abstract "Background: The World health organization (WHO) recently recommended standardized all-oral shorter regimens for rifampicin resistant Tuberculosis (RR-TB). For highly resistant Tuberculosis patients such as pre-XDR-TB: RR-TB plus additional resistance to fluoroquinolones (FQ), the 6–9-months bedaquiline (bedaquiline)-based regimens or BDQ-based long regimens are recommended. The role of second-line injectable (SLI) drugs in the treatment of drug resistant TB is restricted because of safety concerns. Nevertheless, it is not well-known how all-oral long regimens (BDQ-long) perform compared to SLI-containing long regimens (BDQ/SLI-long) in terms of safety and effectiveness among patients with highly resistant TB. Method: A prospective observational cohort of patients with RR-TB additionally resistant to fluoroquinolones and/or second-line injectable, treated with either BDQ-long or BDQ/SLI-long regimens according to the guidance of the National Tuberculosis Program of Vietnam, enrolled between December 2015 and June 2017. Results: Of 99 patients enrolled, 42 (42%) patients were treated with BDQ-long and 57 (57%) with BDQ/SLI-long. More than 85% of patients were previously exposed to both FQ and SLI. FQ and SLI resistance were confirmed in 28 (67%) and 41 (98%) in the BDQ-long cohort and 48 (84%) and 17 (30%) in the BDQ/SLI-long cohort, respectively. Treatment success was achieved among 29 (69%) and 46 (81%) patients on the BDQ-long and BDQ/SLI-long regimen, respectively ( p = 0.2). For both regimens, median time to first smear/culture sputum conversion was 2 months. All patients experienced at least one adverse event (AE) and 85% of them had at least one severe Adverse events. The median time to a first severe adverse event was 2 months. Among patients treated with BDQ-long a higher proportion of patients had three QT-prolonging drugs in the regimen (26.2% versus 7.0%; p = 0.009). The severe prolonged QTcF was observed in 22 (52.4%) and 22 (38.6%) patients on BDQ-long and BDQ/SLI-long, respectively. Overall, 30 (30%) patients had to either temporary or permanently discontinued or more TB drugs due to AEs. Conclusion: Treatment success was similar for both all-oral and SLI-containing BDQ-based long regimens in highly resistant TB patients. Both regimens had a similar high frequency of AEs. For both BDQ-long and BDQ/SLI-long regimens active AEs monitoring is essential." @default.
• W4306160147 created "2022-10-14" @default.
• W4306160147 creator A5000346520 @default.
• W4306160147 creator A5004010707 @default.
• W4306160147 creator A5009329608 @default.
• W4306160147 creator A5013934459 @default.
• W4306160147 creator A5014839628 @default.
• W4306160147 creator A5016622180 @default.
• W4306160147 creator A5019356686 @default.
• W4306160147 creator A5022157840 @default.
• W4306160147 creator A5048842781 @default.
• W4306160147 date "2022-10-14" @default.
• W4306160147 modified "2023-10-02" @default.
• W4306160147 title "Safety and effectiveness of all-oral and injectable-containing, bedaquiline-based long treatment regimen for pre-XDR tuberculosis in Vietnam" @default.
• W4306160147 cites W1988279180 @default.
• W4306160147 cites W2037263659 @default.
• W4306160147 cites W2108960489 @default.
• W4306160147 cites W2791308452 @default.
• W4306160147 cites W2898276975 @default.
• W4306160147 cites W2947164752 @default.
• W4306160147 cites W2979539159 @default.
• W4306160147 cites W2980478680 @default.
• W4306160147 cites W3009599329 @default.
• W4306160147 cites W3013976539 @default.
• W4306160147 cites W3108150642 @default.
• W4306160147 cites W3140357657 @default.
• W4306160147 cites W3154622831 @default.
• W4306160147 cites W3198657815 @default.
• W4306160147 cites W4220799280 @default.
• W4306160147 cites W4280503073 @default.
• W4306160147 cites W4284676046 @default.
• W4306160147 doi "https://doi.org/10.3389/fphar.2022.1023704" @default.
• W4306160147 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36313324" @default.
• W4306160147 hasPublicationYear "2022" @default.
• W4306160147 type Work @default.
• W4306160147 citedByCount "1" @default.
• W4306160147 countsByYear W43061601472023 @default.
• W4306160147 crossrefType "journal-article" @default.
• W4306160147 hasAuthorship W4306160147A5000346520 @default.
• W4306160147 hasAuthorship W4306160147A5004010707 @default.
• W4306160147 hasAuthorship W4306160147A5009329608 @default.
• W4306160147 hasAuthorship W4306160147A5013934459 @default.
• W4306160147 hasAuthorship W4306160147A5014839628 @default.
• W4306160147 hasAuthorship W4306160147A5016622180 @default.
• W4306160147 hasAuthorship W4306160147A5019356686 @default.
• W4306160147 hasAuthorship W4306160147A5022157840 @default.
• W4306160147 hasAuthorship W4306160147A5048842781 @default.
• W4306160147 hasBestOaLocation W43061601471 @default.
• W4306160147 hasConcept C126322002 @default.
• W4306160147 hasConcept C141071460 @default.
• W4306160147 hasConcept C142724271 @default.
• W4306160147 hasConcept C201903717 @default.
• W4306160147 hasConcept C2776301714 @default.
• W4306160147 hasConcept C2777768864 @default.
• W4306160147 hasConcept C2777975735 @default.
• W4306160147 hasConcept C2778607973 @default.
• W4306160147 hasConcept C2779912665 @default.
• W4306160147 hasConcept C2780544761 @default.
• W4306160147 hasConcept C2781069245 @default.
• W4306160147 hasConcept C2781413609 @default.
• W4306160147 hasConcept C71924100 @default.
• W4306160147 hasConcept C72563966 @default.
• W4306160147 hasConceptScore W4306160147C126322002 @default.
• W4306160147 hasConceptScore W4306160147C141071460 @default.
• W4306160147 hasConceptScore W4306160147C142724271 @default.
• W4306160147 hasConceptScore W4306160147C201903717 @default.
• W4306160147 hasConceptScore W4306160147C2776301714 @default.
• W4306160147 hasConceptScore W4306160147C2777768864 @default.
• W4306160147 hasConceptScore W4306160147C2777975735 @default.
• W4306160147 hasConceptScore W4306160147C2778607973 @default.
• W4306160147 hasConceptScore W4306160147C2779912665 @default.
• W4306160147 hasConceptScore W4306160147C2780544761 @default.
• W4306160147 hasConceptScore W4306160147C2781069245 @default.
• W4306160147 hasConceptScore W4306160147C2781413609 @default.
• W4306160147 hasConceptScore W4306160147C71924100 @default.
• W4306160147 hasConceptScore W4306160147C72563966 @default.
• W4306160147 hasLocation W43061601471 @default.
• W4306160147 hasLocation W43061601472 @default.
• W4306160147 hasLocation W43061601473 @default.
• W4306160147 hasOpenAccess W4306160147 @default.
• W4306160147 hasPrimaryLocation W43061601471 @default.
• W4306160147 hasRelatedWork W1987247410 @default.
• W4306160147 hasRelatedWork W2002113121 @default.
• W4306160147 hasRelatedWork W2273634002 @default.
• W4306160147 hasRelatedWork W2584595883 @default.
• W4306160147 hasRelatedWork W2807439384 @default.
• W4306160147 hasRelatedWork W2895817599 @default.
• W4306160147 hasRelatedWork W2911690370 @default.
• W4306160147 hasRelatedWork W2916256405 @default.
• W4306160147 hasRelatedWork W2922915119 @default.
• W4306160147 hasRelatedWork W3142115330 @default.
• W4306160147 hasVolume "13" @default.
• W4306160147 isParatext "false" @default.
• W4306160147 isRetracted "false" @default.
• W4306160147 workType "article" @default.